Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIGNATURE Module 8: Ribociclib in CDK4/6-altered tumors
NCT02187783Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2014
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ribociclib in solid tumor, hematologic malignancy, sponsored by Novartis. Started Aug 2014; status: completed.
02
Drugs
ribociclib
03
Conditions
solid tumorhematologic malignancy
Beyond the preview
Go deeper on NCT02187783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02187783.